Overview

Gender

male

Bruce Burlington is a prominent independent consultant on pharmaceutical product development and regulatory affairs with more than 30 years of experience in regulatory affairs and drug development.

Bruce Burlington’s extensive experience in drug and product development comprises several senior posts at Wyeth, including Executive Vice President and Worldwide Head of Regulatory Affairs, where he played a central role in the development and global registration of many products.

Prior to joining Wyeth, Bruce Burlington was a leader at the US Food and Drug Administration (FDA) where he served for 17 years in various roles, including director of the Division of Biological Investigational New Drugs, several management positions in the Center for Drug Evaluation and Research, and director of the Center for Devices and Radiological Health.

As an infectious disease physician and a leader in regulatory policy, Bruce Burlington has served as the industry representative on the FDA’s Drug Safety and Risk Management Advisory Committee and currently holds Board positions at Cangene Corporation, AstraZeneca, and the International Partnership for Microbicides.

Bruce Burlington graduated from Louisiana Tech University with a B.A. in Psychology and Economics and received his M.D. degree from Louisiana State University.

He completed his internal medicine internship and residency, as well as his infectious disease fellowship, at the University of Colorado.